

# Sean A Fletcher

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1565284/publications.pdf>

Version: 2024-02-01

27  
papers

479  
citations

840776

11  
h-index

713466

21  
g-index

27  
all docs

27  
docs citations

27  
times ranked

1000  
citing authors

#	ARTICLE	IF	CITATIONS
1	Barriers to Quality End-of-Life Care for Patients With Blood Cancers. <i>Journal of Clinical Oncology</i> , 2016, 34, 3126-3132.	1.6	108
2	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. <i>Cancer</i> , 2019, 125, 1449-1458.	4.1	56
3	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 125-136.	3.9	53
4	Contemporary national trends in prostate cancer risk profile at diagnosis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 81-87.	3.9	39
5	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. <i>JAMA Network Open</i> , 2020, 3, e201839.	5.9	37
6	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. <i>Journal of Urology</i> , 2019, 201, 735-741.	0.4	31
7	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 238.e7-238.e17.	1.6	21
8	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. <i>Annals of Surgical Oncology</i> , 2019, 26, 297-305.	1.5	20
9	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. <i>Cancer</i> , 2019, 125, 1319-1329.	4.1	20
10	The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65 years. <i>Cancer</i> , 2020, 126, 496-505.	4.1	19
11	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. <i>World Journal of Urology</i> , 2018, 36, 1767-1774.	2.2	12
12	Use of Preventive Health Services Among Cancer Survivors in the U.S.. <i>American Journal of Preventive Medicine</i> , 2018, 55, 830-838.	3.0	11
13	Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e488-e493.	1.9	11
14	Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. <i>Journal of Oncology Practice</i> , 2019, 15, e547-e559.	2.5	8
15	Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 593-599.	3.9	8
16	Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?. <i>European Urology Oncology</i> , 2019, 2, 349-354.	5.4	6
17	Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 195.e13-195.e18.	1.6	6
18	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 130.e17-130.e24.	1.6	4

#	ARTICLE	IF	CITATIONS
19	Adoption of robotic surgery: driven by market competition or a desire to improve patient care?. <i>Lancet Oncology</i> , 2018, 19, e66.	10.7	2
20	Multiparametric magnetic resonance imaging for prostate cancer detection: do clinical trial findings reflect real-world practice?. <i>BJU International</i> , 2019, 123, 197-198.	2.5	2
21	Workplace absenteeism amongst patients undergoing open vs. robotic radical prostatectomy, hysterectomy, and partial colectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 1644-1650.	2.4	2
22	Immortal-time bias: a crucial yet overlooked confounder in urological research. <i>BJU International</i> , 2017, 120, 455-455.	2.5	1
23	Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 400.e15-400.e22.	1.6	1
24	Using Competing Risk of Mortality to Inform the Transition from Prostate Cancer Active Surveillance to Watchful Waiting. <i>European Urology Focus</i> , 2022, 8, 1141-1150.	3.1	1
25	The new frontier of prostate biopsy: determining the role of image-guidance in moving the needle. <i>BJU International</i> , 2018, 121, 4-5.	2.5	0
26	What Diversity Means. <i>Urology</i> , 2021, , .	1.0	0
27	On the Black-White Disparity in Prostate Cancer Mortality. <i>JNCI Cancer Spectrum</i> , 2022, 6, pkab094.	2.9	0